Checkpoint Therapeutics Inc (CKPT) Stock Price, Quote & News

Company Profile

Checkpoint Therapeutics, Inc., a commercial -stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is UNLOXCYT, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignanci...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 652 4500

Fax: 646 619 4950

Website: checkpointtx.com

Address:

95 Sawyer Road, Suite 110, Waltham, United States

TREBLALBERT Feb. 22 at 11:33 AM

$CKPT Sun has to submit UNLOXCYT's MAA in Europe by May 30, 2026.

0 · Reply

GJ_Rockabilt Jan. 30 at 11:34 AM

$CKPT Today is last day to sign up to for FREE Warrants with every Share of Cancer fighting $TPST . Acquisition in process. Do your own Due Diligence.

0 · Reply

FinSUN Jan. 3 at 11:27 PM

$MIST $CKPT why are you saying that?

1 · Reply

H3rc1y Dec. 17 at 11:16 AM

$MIST Was anyone here in $CKPT ? I'm getting a very very similar vibe here.

1 · Reply

NoEmotionzTrade Dec. 4 at 9:55 PM

$MBIO $FBIO $DERM $CKPT $F watch DEVS, todays news is massive! This can fly over night, SMX vibes. Tiny float, huge news, highly shorted. .............

0 · Reply

EJNap Dec. 3 at 2:13 AM

$CKPT Hopefully they will submit for EMA approval soon. Surprised they will only start commercialization in 2026 🤔 https://trial.medpath.com/news/557f3510f2173f9e/fda-approves-updated-label-for-unloxcyt-based-on-long-term-data-showing-improved-outcomes-in-advanced-cutaneous-squamous-cell-carcinoma?__cf_chl_tk=Gz1CHGQt.jjB.jh7FzdQTyB6iASXP3_xJSwaC3zJQGM-1764726181-1.0.1.1-gPnmeEjeSTWUM7e02H8tYWStLS00Lz8mKq.lKKxsWXQ

0 · Reply

ZSchafes Dec. 1 at 3:38 AM

$ITRM this time last year I got a long awaited but underwhelming buyout for $CKPT. Hoping we can get one here soon for a couple bucks at least.

0 · Reply

Al_Paca Oct. 30 at 5:12 PM

$CKPT $ITRM quiet period can be rough

0 · Reply

H3rc1y Oct. 30 at 4:35 PM

$ITRM I am getting $CKPT PTSD… Still bullish but sometimes the lack of announcements of any short get on my nerves.

1 · Reply

sujeto Sep. 23 at 2:31 PM

$CKPT dead stock

0 · Reply

Market Cap	370.71M
Revenue (ttm)	40,000.00
Net Income (ttm)	-56.24M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-140,600.01%
Debt to Equity Ratio	0.00

Volume	8,666,800
Avg Vol	1,808,080
Day's Range	N/A - N/A
Shares Out	87.02M
Stochastic %K	85%
Beta	1.18
Analysts	Sell
Price Target	$4.45

Checkpoint Therapeutics Inc (CKPT)

Company Profile

Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates

CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT

Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates

Sun Pharma to Acquire Checkpoint Therapeutics

Checkpoint Therapeutics: Updating My Strategy After Unloxcyt's Approval

Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)

Checkpoint Therapeutics: Preparing For Cosibelimab's Upcoming PDUFA Date

Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024

Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Checkpoint Therapeutics: A Binary Bet On FDA Approval And Cosibelimab's Market Success

Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates

Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma

GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research

Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab

Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission

Lifshitz Law PLLC Announces Investigations of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT), Fox Factory Holding Corp. (NASDAQ: FOXF), Snowflake Inc. (NYSE: SNOW), and Nextdoor Holdings, Inc. (NYSE: KIND)

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint

CKPT DEADLINE UPDATE: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

IMPORTANT DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Checkpoint Therapeutics, Inc. (CKPT) on Behalf of Investors

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

The Law Offices of Frank R. Cruz Announces Investigation of Checkpoint Therapeutics, Inc. (CKPT) on Behalf of Investors

Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors

Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market

Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference